https://www.selleckchem.com/pr....oducts/sumatriptan.h
120, indolelactic acid and phenylacetyl-glutamine was identified based on comprehensive discovery and validation workflow. This panel showed favorable discriminating power for PD. This study may help improve our understanding of PD etiopathogenesis and facilitate target screening for therapeutic intervention. The metabolite panel identified in this study may provide novel approach for the clinical diagnosis of PD in the future. This study may help improve our understanding of PD etiopathogenesis and facilitate target screening for t
Like
Comment
Share
